Ubs Ag Etracs Silver Shares Covered Call ETN Exp 21 Apr 2033 vs Stryker Corporation — how do they compare? Ubs Ag Etracs Silver Shares Covered Call ETN Exp 21 Apr 2033 trades at $70.92, while Stryker Corporation trades at $277.44 (market cap $105.63B). The key difference: Stryker Corporation pays a 1.28% dividend while Ubs Ag Etracs Silver Shares Covered Call ETN Exp 21 Apr 2033 pays none, and Ubs Ag Etracs Silver Shares Covered Call ETN Exp 21 Apr 2033 is trading nearer its 52-week high, Stryker Corporation nearer its low. Which is the better fit depends on your goals.
| SLVO | SYK | |
|---|---|---|
Sector | Income / Options Overlay | Technology |
52-Week High | $107.41 | $388.79 |
52-Week Low | $61.81 | $275.39 |
Market Cap | — | $105.63B |
Enterprise Value | — | $117.10B |
Dividend Yield | — | 1.28% |
Signals from Pluang's Aura AI — not financial advice
SLVO trades at $70.01, down 0.44% amid mixed technical signals with a neutral overall rating. The stock recently crossed below its 50-day moving average of $73.20, indicating potential near-term pressure. Silver price volatility and dollar strength are influencing ETN performance, with support levels forming around $69-70.
The outlook remains balanced with technical indicators showing conflicting signals. Silver market dynamics and covered call strategy performance will drive future price action. Key risks include silver price volatility and interest rate sensitivity, while institutional monitoring suggests cautious market positioning.
Stryker (SYK) is trading at $276.43, down 8.81% over 24 hours, with a bearish technical signal from moving averages but bullish oscillators. The company reported mixed quarterly earnings, beating in Q4 2025 and Q2 2026 but missing in Q1 2026. Strong fundamentals include a net income margin of 14.43% and ROE of 16.51%, though valuation ratios like a P/E of 28.65 are elevated. Recent news includes a securities fraud investigation announcement and the launch of an FDA-cleared surgical app for Apple Vision Pro.
The outlook for SYK is supported by solid profitability and growth initiatives like acquisitions and product launches, but near-term risks include the fraud investigation and competitive pressures. Analyst consensus is strongly bullish with a $376 price target, suggesting significant upside potential if the company navigates current challenges successfully.
Trailing returns across standard periods
SLVO is an exchange-traded note issued by UBS AG that provides investors with exposure to the performance of a silver-based covered call strategy. The ETN tracks the daily return of the ISE Enhanced 100x Leveraged Silver ETN Index, which combines a long position in silver with a covered call strategy on the silver position. This strategy aims to generate current income from the option premiums, which can provide a buffer during sideways or slightly down markets for silver, but it also caps the potential gains from a significant rise in silver prices. As an ETN, it is subject to the credit risk of the issuer, UBS AG, and has an expiration date of April 21, 2033.
Read more on SLVO →Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →